Donanemab for early memory and thinking decline with Lewy body features
Tests donanemab against placebo in people with early cognitive decline and Lewy body features.
Key facts
- Who runs it
- Eli Lilly and Company
- Where
- Gangnam-gu, Incheon, Namdong-gu, and Seoul, South KoreaSee the 6 sitesAlso in 3 other countries, 66 sites
- Trial code
- Registry title
- A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 350 people, planned
- Started
- 20 May 2026
- Expected to end
- Aug 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Donanemab
- Placebo
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 55 to 85 with slowly worsening memory and thinking problems and at least one core sign of dementia with Lewy bodies. Tests must show both amyloid and alpha-synuclein changes in the brain.
- Age
- 55 to 85 years
- Sex
- All sexes can join.
- Disease stage
- Gradual, progressive decline in thinking for at least 6 months. At least 1 core clinical feature of dementia with Lewy bodies (DLB). A score of 20 or more on the Montreal Cognitive Assessment (MoCA).
- Earlier treatment
- People who have received amyloid-targeting therapy before cannot join. Active immunization against amyloid-beta is also not allowed.
- Biomarker or test result
- Plasma P-tau217 must meet the criteria. A cerebrospinal fluid (CSF) result must show brain amyloid and also alpha-synuclein.
Main reasons for not taking part
- Another serious or unstable illness that could interfere with the study
- A significant neurological disease other than the one studied
- Cancer with a high risk of coming back
- Multiple or severe drug allergies, or severe reactions after treatment
- Cannot have MRI or PET scans, or a lumbar puncture
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Have gradual and progressive cognitive decline for greater than or equal to ( ≥) 6 months
- Have least 1 core clinical feature of dementia with Lewy bodies (DLB)
- Have a score ≥20 on Montreal Cognitive Assessment (MoCA)
- Meet plasma P-tau217 criteria
- Have a cerebrospinal fluid (CSF) result consistent with the presence of brain amyloid pathology
- Have a CSF result consistent with the presence of alpha-synuclein pathology
- Have at least 1 reliable study partner who will provide written informed consent to participate, is in frequent contact with the participant, and is familiar with overall function and behavior, such as day-to-day activities and cognitive abilities
Who cannot take part
- Have previously received amyloid-targeting therapy
- Have a disease or condition that could interfere with this study or is a current serious or unstable illness
- Have, or is suspected to have, a significant neurological disease (other than the studied condition) that affects the central nervous system and may affect the individual's cognition or ability to complete the study
- Have a history of cancer that, in the investigator's opinion, has a high risk of recurrence and preventing the completion of the study
- Have clinically significant multiple or severe drug allergies, significant atopy, or severe posttreatment hypersensitivity reactions
- Active immunization against amyloid-beta
- Have a centrally read MRI that does not meet study entry criteria
- Have contraindication to MRI or PET scans
- Have any contraindication to lumbar puncture
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 85 years old?
Where in South Korea
Also in 3 other countries, 66 sites
- Gangnam Severance Hospital, Yonsei University Health SystemGangnam-gu, South KoreaContact: Hanna Cho (principal investigator)Not yet recruiting
- Inha University HospitalIncheon, South KoreaContact: Seong Hye Choi (principal investigator)Not yet recruiting
- Gachon University Gil Medical CenterNamdong-gu, South KoreaContact: Kee Hyung Park (principal investigator)Not yet recruiting
- Ewha Womans University Mokdong HospitalSeoul, South KoreaContact: Geon Ha Kim (principal investigator)Not yet recruiting
- Hanyang University Seoul HospitalSeoul, South KoreaContact: Hee-Jin Kim (principal investigator)Not yet recruiting
- Konkuk University Medical CenterSeoul, South KoreaContact: Seol-Heui Han (principal investigator)Not yet recruiting
About the trial
What the trial wants to find out
The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention, and make decisions) and functional (how we are able to perform daily activities) decline. For each participant, the study will last one and a half years.
The 2 groups in the trial
- Donanemab (LY3002813)Treatment being tested
Donanemab (LY3002813) administered as an intravenous (IV) infusion
Treatment: Donanemab
- PlaceboPlacebo, for comparison
Placebo administered IV
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2 Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Donanemab in Participants With Early Cognitive Decline, at Least One Core Clinical Feature of Dementia With Lewy Bodies, and Confirmation of Alpha-Synuclein and Amyloid Co-pathology
- Plain-language title
- Donanemab for early memory and thinking decline with Lewy body featuresGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07589595, who can take part
- Record updated
- 4 November 2026